Company intelligence / Profile preview

Next Gen Pharma

Not specified, New York, United Statescdek.pharmacy.purdue.edu ↗

Ownership: Private
Employees: ~43
Development stage: Phase 3

Overview

Nextgen Pharmaceuticals develops and supplies a portfolio of prescription products across various dosage forms, focusing on oncology, immuno-suppressants, and infusion therapies. The company has FDA-approved products and strategic partnerships to ensure supply continuity for healthcare providers. No specific clinical trial results are disclosed.

Therapeutic areas: OtherOncologyImmunology
Modalities: Infusion therapy productsGeneric prescription medications
Industry: Biotech

Drug pipeline

2 assets

Vivomixx

Phase 3

Indications: Obesity, Irritable Bowel Syndrome, Periodontitis

1 more asset in the full pipeline.

Request access →

Partnerships

Healthcare institutions, clinics, hospitals nationwide for product distributionStrategic partners involved in product development

Beyond the preview

Go deeper on Next Gen Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Next Gen Pharma.

Explore the full profile